Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2026 12:15 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.

The Io Therapeutics, Inc. clinical stage anti-cancer RXR agonist compound demonstrated efficacy in models of human multiple myeloma.
March 25, 2026 11:50 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that...
March 25, 2026 10:11 ET | Source: Nanobiotix S.A.

NANOBIOTIX Statement Regarding Recent Media Speculation

PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic...
March 25, 2026 10:00 ET | Source: Eascra Biotech

Eascra Biotech Takes First Place at TechConnect Bio in Space Innovation Challenge

Eascra Biotech, a nanomedicine startup, has won first place at the TechConnect Bio in Space Innovation Challenge
March 25, 2026 08:30 ET | Source: INVO Fertility, Inc.

INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-5...
March 25, 2026 08:05 ET | Source: Imunon, Inc.

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients...
March 25, 2026 08:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in...
March 25, 2026 08:00 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at...
March 25, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist
March 25, 2026 07:00 ET | Source: Endogenex

Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval

MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical technology company pioneering a new treatment for type 2 diabetes (T2D), today announced the closing of a $50...